Opendata, web and dolomites

ProMeta SIGNED

Non-histone protein acetylation targets of KAT2A in AML

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ProMeta project word cloud

Explore the words cloud of the ProMeta project. It provides you a very rough idea of what is the project "ProMeta" about.

acute    histone    dysregulation    protein    found    alpha    residues    survival    investigation    small    aml    epigenetic    pathogenesis    identity    evi1    break    first    proteins    attributable    coactivator    blasts    acetyltransferase    drug    bone    supportive    patients    modifications    itd    fda    post    yeast    translational    chains    clonal    disease    administration    cell    crucially    designation    peroxisome    decades    ing    modifiers    proliferator       diseases    fate    mutation    acetylates    fusion    driving    activated    flt3    therapy    free    dismal    transplantation    considering    implicated    food    maturation    explore    developmental    oncogenic    acetyl    complexes    extends    care    mds1    pivotal    maintained    gamma    heterogeneous    cancer    prognosis    transferase    gcn5    leukaemia    signalling    paves    expansion    myeloid    rare    hijacked    accompanying    deranged    receptor    remained    catalyse    unchanged    aml1    essentially    stages    mutated    mainstay    reprogramming    pkc412    30    regulates    hat    received    marrow    interests    acetylation    transcriptional    kat2a    function    themes    biology   

Project "ProMeta" data sheet

The following table provides information about the project.

Coordinator
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE 

Organization address
address: TRINITY LANE THE OLD SCHOOLS
city: CAMBRIDGE
postcode: CB2 1TN
website: www.cam.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 183˙454 €
 EC max contribution 183˙454 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) coordinator 183˙454.00

Map

 Project objective

The importance of an insight into how cell fate is established and maintained, extends far beyond the interests of developmental biology. It is pivotal to our understanding of how these processes can be hijacked and deranged in diseases such as cancer, or of the factors involved in reprogramming cell identity and function. Acute Myeloid Leukaemia (AML) has a dismal prognosis with less than 30% 5-year survival. Mainstay therapy has remained essentially unchanged for the past three decades, with all small advances in disease-free survival attributable to transplantation and improved supportive care. Only recently PKC412 has received Food and Drug Administration (FDA)’s break through therapy designation for the FLT3-ITD AML. This paves the way for investigation considering that FLT3-ITD as a driving oncogenic mutation has been found in ~30% of the AML patients. The pathogenesis of AML is heterogeneous, but there are common themes of epigenetic, transcriptional and signalling dysregulation that contribute to the resulting clonal expansion of blasts at different stages of maturation, and accompanying bone marrow failure. A significant number of the most commonly mutated targets in AML are histone modifiers, i.e. proteins or complexes that catalyse post-translational modifications in specific residues of the histone side chains. A less studied acetyltransferase, but crucially implicated in AML is KAT2A, the first histone acetyl-transferase (HAT) identified in yeast.GCN5 also acetylates the AML1/MDS1/EVI1 fusion protein in rare cases of AML.KAT2A regulates the activity of Peroxisome Proliferator- Activated Receptor Gamma-Coactivator-1α and B through protein acetylation. The goal of this proposal is to explore the role of KAT2A in Acute Myeloid Leukaemia (AML) through investigation of its non-histone protein acetylation activity.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROMETA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PROMETA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

STIMOS (2019)

Stimulation of Multiple Organoids Simultaneously

Read More  

BirthControlEnvirons (2019)

Contraception meets the environment: everyday contraceptive practices, politics, and futures in a toxic age

Read More  

MarshFlux (2020)

The effect of future global climate and land-use change on greenhouse gas fluxes and microbial processes in salt marshes

Read More